# Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

> **NCT04677439** · PHASE4 · UNKNOWN · sponsor: **Shenzhen Second People's Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Flumatinib
- Chronic Myeloid Leukemia, Chronic Phase
- Imatinib

## Interventions

- **DRUG:** Flumatinib

## Key facts

- **NCT ID:** NCT04677439
- **Lead sponsor:** Shenzhen Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677439, "Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT04677439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*